英国常规免疫规划中4CMenB疫苗上市后安全性观察研究
该研究利用英国THIN初级保健电子记录数据库(2015—2018年),采用自身对照病例系列分析,评估107,231名1—18月龄儿童接种4CMenB疫苗后的安全性。结果显示,接种后0—6天癫痫发作和热性惊厥的调整发病率比分别为1.43(95%CI:1.02—2.02)和1.72(95%CI:1.08—2.75),但多数4CMenB与其他疫苗同时接种,无法归因于单一疫苗。
要点
- 4CMenB接种后0—6天癫痫发作风险升高,调整发病率比1.43(95%CI:1.02—2.02)。
- 热性惊厥风险亦升高,调整发病率比1.72(95%CI:1.08—2.75)。
- 多数4CMenB与其他疫苗同时接种,无法将风险归因于单一疫苗。
核心结论
- 接种4CMenB后癫痫发作和热性惊厥风险轻度升高,但因多同时接种其他疫苗,无法归因于单一疫苗。
研究设计与样本
- 利用英国THIN初级保健电子记录数据库(2015—2018年)开展自身对照病例系列分析。
- 共纳入107,231名1—18月龄儿童,接受至少1剂4CMenB疫苗接种。
主要发现
- 在239,505剂次接种后0—6天发生43例癫痫发作,调整发病率比1.43(95%CI:1.02—2.02)。
- 在239,505剂次接种后0—6天发生23例热性惊厥,调整发病率比1.72(95%CI:1.08—2.75)。
- 在194,929剂次接种后1—28天发生4例川崎病,病例数不足以建模。
- 过敏性休克、吉兰-巴雷综合征和急性播散性脑脊髓炎在风险期内无病例报告。
临床怎么用
- 预防医学与公共卫生医生应知晓4CMenB接种后癫痫发作和热性惊厥风险轻度升高。
- 因多数4CMenB与其他疫苗同时接种,监测异常反应时需综合考虑联合接种因素。
局限性
- 川崎病病例数不足,无法进行建模分析。
- 多数4CMenB与其他疫苗同时接种,无法将风险归因于单一疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The study investigated the safety of 4-component meningococcal serogroup B vaccination (4CMenB) in routine care. 4CMenB exposure and seizures, febrile seizures and Kawasaki disease were identified from The Health Improvement Network (THIN) database of UK electronic primary healthcare records, 2015-2018. A self-controlled case series analysis was completed. Anaphylaxis, Guillain-Barré syndrome and acute disseminated encephalomyelitis were secondary outcomes. A total of 107,231 children aged 1-18 months received ≥1 doses of 4CMenB vaccination. Most 4CMenB exposure (93%) was on the same day as other vaccines within a complete national immunisation program stage. With day 0 as day of vaccination, 43 seizures occurred in days 0-6 after 239,505 doses, and 23 febrile seizures occurred in days 0-6, and 4 Kawasaki disease cases in days 1-28 after 194,929 4CMenB doses. Adjusted incidence rate ratios including all 4CMenB exposures were 1.43 (95%CI: 1.02-2.02) for seizures and 1.72 (95%CI: 1.08-2.75) for febrile seizures. There were insufficient cases to model Kawasaki disease, and no cases of the secondary outcomes in risk periods when they may be associated with the vaccination. This study shows few cases of the outcomes after vaccination including 4CMenB with an increased risk of seizures and febrile seizures. It is not possible to attribute the finding to one specific vaccination as the majority of 4CMenB was given with other vaccinations. Trial registration: NA.
引用
- Hall GC, Douglas I, Heath PT, et al. Post-licensure observational safety study after meningococcal B vaccine 4CMenB (Bexsero) vaccination within the routine UK immunisation program. Vaccine. 2021. PMID: 33962840. doi:10.1016/j.vaccine.2021.02.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。